This novel treatment, nearing Phase 1 clinical trials, could help prevent weight regain post-GLP-1 analogue use by mimicking the incretin hormone to suppress appetite and regulate blood sugar, thus aiding in the management of obesity and diabetes
As GLP-1 receptor agonists, they can affect the bodys absorption of oral medications
However, individual responses can vary, and any new symptoms should be discussed with a healthcare provider
[DOI] [PubMed] [Google Scholar] 18.Hansen-Smith FM, Watson L, Lu DY, Goldstein I
Many patients find that eating smaller, more frequent meals rather than three large ones feels better when both conditions are present